Drug Trial Radar · NCT00684177
Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)
Last checked: Nov 20, 2026Latest source record: Nov 23, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
508
Actual
Start
May 2008
Primary completion
Oct 2009
Study completion Oct 2009
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- May 26, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of Study TOC110977 is to demonstrate clinical superiority of Retapamulin ointment, 1%, over placebo in patients with secondarily-infected traumatic lesions, which includes secondarily-infected lacerations, abrasions and sutured wounds. Subjects 2 months of age and older will be treated with topical retapamulin or placebo ointment twice daily for 5 days. The primary endpoint of this study is the clinical response at follow-up (Day 12-14; 7-9 days after the end of therapy) in the intent-to-treat clinical population.
Conditions
- Skin Infections, Bacterial
Interventions
Retapamulin Ointment, 1%Drug
Provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse taper puncture tip caps.
Placebo ointmentDrug
Provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse taper puncture tip caps.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Clinical Success and Failure at Follow-up (7-9 Days Post Therapy) for the Primary Efficacy PopulationTime frame: Days 12-14
Locations
54 sites in 5 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Anaheim, California
GSK Investigational Site
Fresno, California
GSK Investigational Site
Irvine, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Sacramento, California
GSK Investigational Site
Colorado Springs, Colorado
GSK Investigational Site
Deerfield Beach, Florida
GSK Investigational Site
Hollywood, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
Panama City, Florida
GSK Investigational Site
Tampa, Florida
GSK Investigational Site
Vero Beach, Florida
GSK Investigational Site
West Palm Beach, Florida
GSK Investigational Site
Arlington Heights, Illinois
GSK Investigational Site
Kansas City, Kansas
GSK Investigational Site
New Orleans, Louisiana
GSK Investigational Site
Butte, Montana
GSK Investigational Site
Teaneck, New Jersey
GSK Investigational Site
Brooklyn, New York
GSK Investigational Site
Brooklyn, New York
GSK Investigational Site
East Syracuse, New York
GSK Investigational Site
Johnson City, New York
GSK Investigational Site
Cincinnati, Ohio
GSK Investigational Site
Norristown, Pennsylvania
GSK Investigational Site
Uniontown, Pennsylvania
GSK Investigational Site
Greenville, South Carolina
GSK Investigational Site
Houston, Texas
GSK Investigational Site
Bountiful, Utah
GSK Investigational Site
Vienna, Virginia
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Buenos Aires, Buenos Aires, Argentina
GSK Investigational Site
Chivilocoy, Buenos Aires, Argentina
GSK Investigational Site
Loma Hermosa, Buenos Aires, Argentina
GSK Investigational Site
Curitiba, Paraná, Brazil
GSK Investigational Site
Curitiba/Paraná, Paraná, Brazil
GSK Investigational Site
Passo Fundo, Rio Grande do Sul, Brazil
GSK Investigational Site
Bangalore, India
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.